Anal Cancer

Standard Therapy for Anal Cancer May Not Affect Long-term Outcomes Among HIV Patients

Standard Therapy for Anal Cancer May Not Affect Long-term Outcomes Among HIV Patients

By

Healthy HIV-positive patients with anal cancer are treated with standard chemoradiotherapy, but whether this patient population experiences worse outcomes or more severe toxic effects was previously unknown.

Phase 1b/2 Study of DPX-E7 + Cyclophosphamide in HPV-positive Cancers

Phase 1b/2 Study of DPX-E7 + Cyclophosphamide in HPV-positive Cancers

By

Researchers are evaluating whether DPX-E7 vaccination is safe and will improve outcomes among patients with HPV-positive head and neck, cervical, or anal cancer.

Nivolumab Active in Squamous Cell Carcinoma of the Anal Canal

Nivolumab Active in Squamous Cell Carcinoma of the Anal Canal

By

Nivolumab was clinically active and well-tolerated among patients with treatment-refractory metastatic squamous cell carcinoma of the anal canal (SCCA).

Adding Cetuximab to HIV-associated SCCAC Therapy May Reduce LRF

Adding Cetuximab to HIV-associated SCCAC Therapy May Reduce LRF

By

Addition of cetuximab to definitive chemoradiation (CRT) reduces locoregional failure rates but is associated with grade 4 toxicity.

Higher Facility Volume Linked to Improved OS Among Patients With Anal Cancer

Higher Facility Volume Linked to Improved OS Among Patients With Anal Cancer

By

Care at radiation oncology centers with a higher volume is associated with improved survival among patients with squamous cell carcinoma of the anal canal.

Patterns in PI3K Signaling Pathway Aberrations Evaluated

Patterns in PI3K Signaling Pathway Aberrations Evaluated

By

Researchers argue that combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated across cancer types.

Incidence Rates for Anal Carcinoma, Adenocarcinoma Have Increased Significantly

Incidence Rates for Anal Carcinoma, Adenocarcinoma Have Increased Significantly

Incidence rates (IRs) of anal squamous cell carcinoma (SCC) and squamous carcinoma in situ (CIS) have significantly increased overtime.

HPV Type 16 Seropositivity Common Before Anal Cancer

HPV Type 16 Seropositivity Common Before Anal Cancer

Human papillomavirus (HPV) type 16 (HPV16) seropositivity is relatively common before anal cancer diagnosis.

Gardasil 9 HPV Vaccine Approved

Gardasil 9 HPV Vaccine Approved

The FDA has approved Gardasil 9 (9-valent human papillomavirus types) vaccine for the prevention of cervical, vulvar, vaginal, anal cancers.

Human Papilloma Virus and Squamous Cell Carcinoma of the Anus

Human Papilloma Virus and Squamous Cell Carcinoma of the Anus

[Clin Med Insights Oncol] HPV is a risk factor for anal intraepithelial neoplasia (AIN). Etiology, anatomy, pathogenesis, management of squamous cell carcinoma (SCC) discussed.

For HPV-Associated Anal Cancer, ADXS-HPV Immunotherapy May Be Effective

For HPV-Associated Anal Cancer, ADXS-HPV Immunotherapy May Be Effective

Results of ADXS-HPV with standard chemo and radiotherapy for HPV-associated anal cancer who have a high risk of recurrence.

HPV Screening Linked to Increased U.S. Cases of Anal Canal Carcinoma

HPV Screening Linked to Increased U.S. Cases of Anal Canal Carcinoma

Increased screening and changing demographics may explain the sharp rise in cases of squamous cell carcinoma of the anal canal and anal carcinoma in situ.

Anal Cancer Increase Linked to HIV Infection Only in Men

Anal Cancer Increase Linked to HIV Infection Only in Men

Increased annual incidence of anal cancer in women is not influenced by HIV infection.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs